Puma Biotechnology (NASDAQ:PBYI) Given Daily Media Impact Score of 0.18

Media headlines about Puma Biotechnology (NASDAQ:PBYI) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Puma Biotechnology earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.1568034394134 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern’s analysis:

Shares of Puma Biotechnology (NASDAQ PBYI) traded up $0.45 during trading on Wednesday, reaching $74.25. 557,047 shares of the company’s stock traded hands, compared to its average volume of 1,010,000. Puma Biotechnology has a twelve month low of $28.35 and a twelve month high of $136.90. The firm has a market cap of $2,790.00, a PE ratio of -9.45 and a beta of 0.26.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, topping the consensus estimate of ($1.98) by $0.27. The business had revenue of $21.60 million during the quarter, compared to analyst estimates of $20.83 million. During the same quarter last year, the firm earned ($1.22) EPS. equities research analysts anticipate that Puma Biotechnology will post -3.86 earnings per share for the current fiscal year.

Several brokerages recently commented on PBYI. Stifel Nicolaus set a $95.00 target price on shares of Puma Biotechnology and gave the stock a “buy” rating in a report on Friday, March 9th. BidaskClub downgraded shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Saturday, March 3rd. Credit Suisse Group set a $106.00 target price on shares of Puma Biotechnology and gave the stock a “buy” rating in a report on Friday, March 2nd. Barclays reduced their target price on shares of Puma Biotechnology from $92.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, March 2nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Puma Biotechnology from $138.00 to $91.00 and set a “buy” rating for the company in a report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. Puma Biotechnology has a consensus rating of “Buy” and an average target price of $103.11.

In other news, insider Alan H. Auerbach sold 10,692 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total value of $991,683.00. Following the completion of the transaction, the insider now directly owns 4,155,931 shares in the company, valued at approximately $385,462,600.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Richard Paul Bryce sold 1,860 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total transaction of $172,515.00. Following the completion of the transaction, the senior vice president now owns 25,379 shares of the company’s stock, valued at $2,353,902.25. The disclosure for this sale can be found here. 21.10% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was first published by Equities Focus and is the sole property of of Equities Focus. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.equitiesfocus.com/2018/03/14/puma-biotechnology-pbyi-receives-media-impact-score-of-0-18.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply